Biocomposites Partners with NuVasive on STIMULAN Distribution in Germany

By Julie A. Vetalice

Biocomposites Partners with NuVasive on STIMULAN Distribution in Germany

Biocomposites signed an exclusive distribution agreement with NuVasive Specialized Orthopedics (NSO) to sell its STIMULAN® products in Germany.

STIMULAN is the only calcium matrix to receive CE Mark approval for mixing with antibiotics vancomycin, tobramycin and gentamicin for use in bone and soft tissue. It offers the flexibility to apply a broad spectrum of off-the-shelf antibiotics at the site of infection, at concentration levels unachievable systemically - which can lower rates of reinfection, saves cost and improves patient outcomes.

STIMULAN is used in over 50,000 cases every year, globally.

Michael Harris, Chief Executive Officer of Biocomposites, said, "Germany is Europe's largest orthopaedic reconstruction market and is an important element of Biocomposites' international growth strategy. NSO, with their impressive track record of delivering innovative treatments to patients and strong surgeon relationships, are the ideal partner to distribute STIMULAN to hospitals and surgeons treating infected and high-risk patients."

Source: Biocomposites

Product Labels: Synthetic Bone Graft